Outcomes Improved When Targeted Cancer Therapies Based on Multigene Panel
Progression-free survival rates are higher in patients treated with targeted therapies based on results of multigene panel tests.
Diagnosis & Disease Information
Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.
Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
GARD: A Move Toward Precision Radiation Therapy
A new tool may enable oncologists to deliver radiation therapy targeted to a tumor’s biology and radiosensitivity, similar to how anticancer agents target specific tumor mutation-affected gene pathways.
New Targeted Therapy with a Double-Pronged Approach
A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .
PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma
Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer
Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.
Rare Mutations in Immune-Related Genes Linked to Multiple Simultaneous Colorectal Cancer Tumors
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.
Surgery Improves Survival in Metastatic Kidney Cancer, But Is Little Used
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...